Abstract 395P
Background
Uncommon EGFR mutations show heterogeneity in their EGFR TKI sensitivities.1 Afatinib has shown broad inhibitory activity against uncommon mutations in vitro,1 and clinical activity against major uncommon mutations (G719X/L861Q/S768I).2 However, clinical data regarding the efficacy of afatinib against other uncommon EGFR mutations are lacking, particularly between ethnicities.
Methods
This pooled analysis assessed afatinib activity in Asian/non-Asian, EGFR TKI-naïve pts with NSCLC and uncommon EGFR mutations, treated in RCTs and real-world studies. Uncommon mutations were classed as: de novo T790M; exon 20 insertions (Ins20); major uncommon mutations (G719X/L861Q/S768I); compound mutations (≥2 uncommon mutations); and other uncommon mutations. Key endpoints were overall response rate (ORR), duration of response (DoR), and time to treatment failure (TTF).
Results
Of the 178/120 Asian/non-Asian pts with uncommon EGFR mutations, 62/35% had a major uncommon mutation (G719X only: 20/20%; L861Q only: 26/8%; S768I only: 3/4%), 16/39% had an Ins20 mutation. Clinical activity (Asian/non-Asian) was observed against major uncommon mutations (ORR: 66/59%; median DoR: 14.7/15.9 mos; G719X: 62/65%; L861Q: 60/50%; S768I: 80/25%), compound mutations (ORR: 81/100%; median DoR: 11.5/18.6 mos) and other uncommon mutations (ORR: 79/60%; median DoR: 9.0/10.7 mos). Some pts with Ins20 responded (21/23%). TTF was longest in pts with compound mutations, particularly non-Asian pts (median 18.5 mos).
Conclusions
Afatinib is effective in pts with NSCLC with major uncommon and compound EGFR mutations, with broad activity against other uncommon EGFR mutations and some Ins20 mutations, unaffected by ethnicity. Asian pts appeared to have a high proportion of major uncommon mutations, known to be highly sensitive to afatinib.2 1. Kohsaka S, et al. Sci Transl Med 2017;9:eaan6566 2. Yang JC, et al. Lancet Oncol 2015;16:830‒8 Table: 395P
Patients*, n (%) | ORR, % | TTF, mos (95% CI) | ||||
Asian (N=178) | Non-Asian (N=120) | Asian | Non-Asian | Asian | Non-Asian | |
Major uncommon (MU)† | 110 (61.8) | 42 (35.0) | 66 | 59 | 11.5 (11.5, 13.8) | 9.0 (4.6, 15.4) |
G719X | 36 (20.2) | 24 (20.0) | 62 | 65 | 11.5 (9.6, 17.1) | 9.0 (3.2, 18.7) |
L861Q | 46 (25.8) | 9 (7.5) | 60 | 50 | 11.5 (11.1, 11.5) | 5.7 (1.4, 10.7) |
S768I | 5 (2.8) | 5 (4.2) | 80 | 25 | NR (2.6, NR) | 15.6 (3.0, 20.7) |
Compound | 26 (14.6) | 8 (6.7) | 81 | 100 | 11.5 (8.2, 16.6) | 18.5 (1.6, NR) |
Ins20 | 29 (16.3) | 47 (39.2) | 21 | 23 | 4.5 (2.6, 5.4) | 3.9 (2.8, 5.4) |
Any de novo T790M | 19 (10.7) | 14 (11.7) | 38 | 17 | 4.7 (1.2, 5.5) | 2.9 (0.9, 6.7) |
Other | 17 (9.6) | 13 (10.8) | 79 | 60 | 7.2 (1.8, 11.9) | 10.7 (2.0, 24.0) |
*Patients may be included in >1 group; †Includes patients with MU + Del19/L858R compound mutations.
.Clinical trial identification
Editorial acknowledgement
Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Nadia Fowler, of GeoMed, an Ashfield company, part of UDG Healthcare plc.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
J.C-H. Yang: Honoraria (institution), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (institution), Advisory/Consultancy: Novartis; Honoraria (institution), Advisory/Consultancy: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Roche/Genentech; Honoraria (institution), Advisory/Consultancy: Lilly; Honoraria (institution), Advisory/Consultancy: MSD Oncology; Honoraria (institution), Advisory/Consultancy: Merck Serono; Honoraria (institution), Advisory/Consultancy: Celgene; Honoraria (institution), Advisory/Consultancy: Bayer; Honoraria (institution), Advisory/Consultancy: Pfizer; Honoraria (institution), Advisory/Consultancy: Ono Pharmaceutical; Honoraria (institution), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (institution), Advisory/Consultancy: Yuhan; Honoraria (institution), Advisory/Consultancy: Hansoh; Honoraria (institution), Advisory/Consultancy: Brueprint Medicines; Honoraria (institution), Advisory/Consultancy: Daiichi Snakyo; Honoraria (institution), Advisory/Consultancy: Amgen; Honoraria (institution), Advisory/Consultancy: Takeda Oncology; Honoraria (institution), Advisory/Consultancy: Incyte; Honoraria (institution), Advisory/Consultancy: H: Boehringer Ingelheim; Roche; MSD; AstraZeneca; Novartis; Bristol-Myers Squibb; Ono Pharmaceutical; Takeda Oncology; Eli Lilly; Pfizer. M. Schuler: Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy: Janssen; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy: Roche; Advisory/Consultancy: Takeda; Honoraria (self): Amgen; Honoraria (self): MSD; Honoraria (self): Pierre Fabre. S. Popat: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Takeda; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AZ; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Guardant Health; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Lilly; Honoraria (self), Advisory/Consultancy: EMD Serono; Honoraria (self), Advisory/Consultancy: AbbVie; Honoraria (self), Advisory/Consultancy: Incyte; Honoraria (self), Advisory/Consultancy: Paradox; Research grant/Funding (institution): Ariad. S. Miura: Advisory/Consultancy, Speaker Bureau/Expert testimony: Chugai Pharma; Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Speaker Bureau/Expert testimony: Boehringer Ingelheim; Speaker Bureau/Expert testimony: Taiho Pharma; Speaker Bureau/Expert testimony: Ono Pharma; Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Speaker Bureau/Expert testimony: Novartis; Speaker Bureau/Expert testimony: AbbVie; Speaker Bureau/Expert testimony: Kyowa Hakko Kirin. S. Heeke: Honoraria (self): Boehringer Ingelheim; Honoraria (self): Qiagen; Travel/Accommodation/Expenses: Roche. A. Passaro: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy: BMS; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Dako. K. Park: Advisory/Consultancy: Amgen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): AZ; Advisory/Consultancy, Speaker Bureau/Expert testimony: BI; Advisory/Consultancy: BMS; Advisory/Consultancy: Daiichi Sankyo; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: JNJ; Advisory/Consultancy: Merck KGaA; Advisory/Consultancy: MSD; Advisory/Consultancy: Roche; Research grant/Funding (self): MSD Research. E.S. Kim: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Merck; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Takeda; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
297P - Factors affecting duration of admission in the palliative medicine ward of a tertiary cancer hospital: A pilot, investigator initiated, review of services
Presenter: Rahul D. Arora
Session: e-Poster Display Session
298P - Abandonment of treatment in teenagers and young adults with cancer: A multi institutional survey
Presenter: B S Ankit
Session: e-Poster Display Session
304P - Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors
Presenter: Jian-Guo Zhou
Session: e-Poster Display Session
305P - Novel co-occurring genomic alterations associated with prediction and prognosis in lung adenocarcinoma
Presenter: Xin Zhao
Session: e-Poster Display Session
306P - Detection of anaplastic lymphoma kinase (ALK) mutations using circulating tumour DNA (ctDNA) in advanced non-squamous non-small cell lung cancer (non-Sq-NSCLC) in Asia
Presenter: Kirsty Lee
Session: e-Poster Display Session
307P - Development of circulating free DNA methylation markers for thyroid nodule diagnostics
Presenter: Shuibing Hong
Session: e-Poster Display Session
308P - The genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumour DNA (ctDNA) in clinical practice
Presenter: Byoung Cho
Session: e-Poster Display Session
309P - Improved diagnostic accuracy in MRI breast lesions using a classification system and multilayer perceptron neural network
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
310P - Genomic biomarker detection in East Asian clinical practice using circulating tumour DNA (ctDNA) from patients with gastrointestinal (GI) tract cancers
Presenter: Sadakatsu Ikeda
Session: e-Poster Display Session
311P - Effect of chemotherapy on fatty liver occurrence in breast and gastrointestinal cancer patients
Presenter: Seyed Alireza Javadinia
Session: e-Poster Display Session